Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Abstract: The present invention provides an aptamer that binds to an autotaxin, which contains a nucleotide sequence represented by the following formula (I): CGGAACC-N1-GGTC??(I) wherein N1 shows any of 3 to 11 nucleotides, and a utilization method thereof.

Abstract: The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond, X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, and X3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Abstract: The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond, X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, and X3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.

Abstract: A method for establishing an encrypted communication channel between a first apparatus and a second apparatus by using a session management apparatus. The method includes: establishing a first encrypted communication channel between the session management apparatus and the first apparatus by performing mutual authentication between the session management apparatus and the first apparatus; establishing a second encrypted communication channel between the session management apparatus and the second apparatus by performing mutual authentication between the session management apparatus and the second apparatus; and exchanging key information between the first apparatus and the second apparatus via the first encrypted communication channel and the second encrypted communication channel so as to establish an encrypted communication channel between the first apparatus and the second apparatus.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: Provided is a high-quality aptamer against midkine. An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.

Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by inhibiting MK expression or its activity, thereby increasing the number of regulatory T cells. Furthermore, it was found that diseases associated with the functional disorder of regulatory T cells can be treated with the administration of an inhibitor that inhibits MK expression or activity.

Abstract: Provided is a high-quality aptamer against midkine. An aptamer possessing an inhibitory activity against midkine; a complex comprising an aptamer possessing a binding activity or inhibitory activity against midkine and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like); a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, labeling agent and the like comprising an aptamer possessing a binding activity or inhibitory activity against midkine, or a complex comprising the aptamer and a functional substance; a cell migration inhibitor, a diagnostic reagent, a labeling agent and the like.

Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.

Abstract: A method for establishing an encrypted communication channel between a first apparatus and a second apparatus by using a session management apparatus. The method includes: establishing a first encrypted communication channel between the session management apparatus and the first apparatus by performing mutual authentication between the session management apparatus and the first apparatus; establishing a second encrypted communication channel between the session management apparatus and the second apparatus by performing mutual authentication between the session management apparatus and the second apparatus; and exchanging key information between the first apparatus and the second apparatus via the first encrypted communication channel and the second encrypted communication channel so as to establish an encrypted communication channel between the first apparatus and the second apparatus.

Abstract: A communication scheme capable of guaranteeing the order of packets in the communication media exchange during the communication so as to be able to continue the communication smoothly even after the communication media exchange is disclosed. The source host transmits a first check packet through the first communication path and stops transmission of user data packets upon transmitting the first check packet, while the destination host transmits the first check packet through the second communication path upon receiving the first check packet through the first communication path while transmitting a second check packet through the first communication path, and stops transmission of user data packets upon transmitting the second check packet.

Abstract: An L2 integrated access (L2IA) system is constructed from: L2IA subscribers for supporting communications between user terminals using various communication media, each L2IA subscriber having an L2IA identifier for uniquely identifying each L2IA subscriber within the L2 integrated access system and a terminal ID for uniquely identifying each L2IA subscriber within each communication medium associated with each L2IA subscriber; and an L2IA relay network formed by relay units to be connected with the L2IA subscribers through various communication media and relaying communications between the L2IA subscribers through the L2IA relay network, each relay unit being provided in correspondence to one communication medium such that at least one relay unit is provided in correspondence to each communication medium, and each relay unit having an L2IA relay ID for uniquely identifying each relay unit within the L2IA relay network and a terminal ID for uniquely identifying each relay unit within each communication medium

Abstract: A packet multiplexer capable of realizing the optimization of a communication path automatically, without requiring a user to explicitly specify for it, is disclosed. The packet multiplexer is formed by a plurality of first communication interfaces for terminating a plurality of C-plane and U-plane pairs on one side of the packet multiplexer, a second communication interface for terminating a single C-plane and a plurality of U-planes on another side of the packet multiplexer, a connection interface for multiplexing the C-plane and U-plane pairs terminated at the first communication interfaces into the single C-plane and the plurality of U-planes terminated at the second communication interface, and a control unit for controlling multiplexing of U-planes by the connection interface according to signaling through C-planes, such that a cut-through is made within the packet multiplexer between two U-planes terminated at the first communication interfaces that form a loop.

Abstract: An information distribution device selection system capable of selecting one information distribution device that is logically closest from the user communication terminal among a plurality of information distribution devices on inter-connected communication networks is disclosed.